Opinion editor's note: Editorials represent the opinions of the Star Tribune Editorial Board, which operates independently from the newsroom.
•••
The COVID-19 virus' course and evolution remain unpredictable. But this far into the pandemic, there are some safe assumptions.
One of them is a fall-winter spike in cases. Colder weather's return, schools resuming and holiday gatherings contribute to the crowded indoor conditions that fuel viral spread. A look back at case counts since the pandemic's 2020 start confirms this, with hospitalizations and deaths rising during this time frame.
The pandemic's third autumn is looming. That reality makes this an alarming time for Congress to let one of the best tools to fight COVID's spread — rapid, at-home tests — become less accessible and affordable. The nation's policymakers need to reverse this mistake as soon as possible.
By now, the names of over-the-counter COVID test kits should be familiar. They include BinaxNOW, iHealth, QuickVue, Flowflex and InteliSwab, just to name a few. The products are available on Amazon, at pharmacies and retailers such as Target and Walmart.
Results typically are available in about 15 minutes. The convenience and speed make it easy to determine if you or a family member should isolate instead of going to school, to the office or to a family gathering. If you're positive, staying home can break the chain of this airborne virus's spread.
But the tests' price tag can be daunting. A box of two Binax tests costs $23.99 at Walgreens, for example. During a surge, these tests can also be hard to find. Retailers' shelves emptied quickly in Minnesota last January when the omicron variant hit. Even online supplies were elusive for a time.